Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD0780 dose 1 administered orally to male and female participants (females of non-childbearing potential) with moderate hepatic impairment and mild hepatic impairment (optional) compared with male and female participants (females of non-childbearing potential) with normal hepatic function. Participants will be enrolled within the following groups based on their Child Pugh classification score as determined at screening: * Group 1: Participants with moderate hepatic impairment (Child Pugh Class B, score of 7 to 9). * Group 2: Participants with normal hepatic function demographically matched by sex, age, and body mass index (BMI) to the impaired participants. * Group 3 (optional): Participants with mild hepatic impairment (Child Pugh Class A, score of 5 or 6).